- Published at
- by investing.com
mixed
mixed
News for Mochida Pharmaceutical Co., Ltd. (4534.T)
- Published at
- by investing.com
positivepositiveNxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan By Investing.com
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan- Published at
- by investing.com
negativenegativeNxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia By Investing.com
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia- Published at
- by globenewswire.com
mixedmixedGlobal Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51%
The Global Anal Fissure Treatment Market Size was Valued at USD 1161.3 Million in 2023 and the Worldwide Anal Fissure Treatment Market Size is Expected to...- Published at
- by globenewswire.com
mixedmixedIdorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for...- Published at
- by globenewswire.com
mixedmixedIdorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 25. Juli 2023 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für das erste Halbjahr 2023...- Published at
- by globenewswire.com
mixedmixedIdorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results...- Published at
- by marketscreener.com
mixedmixedIdorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand
Ad hoc announcement pursuant to Art. 53 LR Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand Allschwil, Switzerland – October 25,... | October 25, 2022- Published at
- by globenewswire.com
mixedmixedGlobal Anal Fissure Treatment Market to Acquire Significant Revenue by 2031 and to Grow with a CAGR of ~7% During 2022-2031; Rising Geriatric and Pediatric Constipation Patients to Elevate Market Grow
Key Companies Outlined in the Global Anal Fissure Treatment Market Research Report by Kenneth Research Include AstraZeneca, SLA Pharma AG, Eisai Co., Ltd.,...- Published at
- by prnewswire.com
mixedmixedInsights on the Clot Buster Drugs Global Market to 2027 - Increasing Prevalence of Cardiovascular Diseases Such as Heart Attacks and Strokes is Driving Growth
/PRNewswire/ -- The "Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type, By Application, By...- Published at
- by gurufocus.com
positivepositiveFranklin Templeton ETF Trust Buys Toyota Motor Corp, Sony Group Corp, Keyence Corp, Sells Gunma Bank, Nippon Paper Industries Co, Kyoritsu Maintenance Co
GuruFocus Article or News written by insider and the topic is about: